HPLC purity
Reverse-phase HPLC with UV detection; purity target reported per lot with related-substance reporting on request.
Pepti · Catalog · CJC-1295 without DAC + Ipamorelin
GH-secretagogue blend · research-use
Lyophilized GHRH-analog and ghrelin-receptor-agonist blend in 10 mg vials, supplied to research labs and private-label brands with a batch-linked COA containing chromatographic purity and component molecular-weight identity results.
Vial illustrations reflect supplied lyophilized format. Distribution scope and destination market confirmed before invoicing.
| Compound | CJC-1295 without DAC + Ipamorelin |
|---|---|
| Form | Lyophilized powder, glass vial |
| Purity target | ≥ 99% by HPLC |
| Vial formats | 10mg |
| Documentation | Batch-linked COA containing chromatographic purity and molecular-weight identity results for the confirmed lot |
| Distribution scope | Research use, worldwide |
| Storage | Lyophilized powder stable at 2–8 °C protected from light; −20 °C for long-term storage. After reconstitution with bacteriostatic water, keep refrigerated and use within the validated window. |
| Tier | Quantity | Lead time |
|---|---|---|
| Sample lot | 1 kit (10 vials) | 3–7 days |
| Production lot | 200–1,000 vials | 10–14 days |
| OEM repeat | 1,000+ vials | 14–18 days, scheduled |
Supplied as a research-use peptide. Every quote confirms current-batch COA, purity, destination market and buyer track before invoicing.
Overview
The blend combines two growth-hormone secretagogues that act on complementary receptors: CJC-1295 without DAC (Modified GRF 1-29) is a synthetic growth-hormone-releasing hormone (GHRH) analog that binds the GHRH receptor, while ipamorelin is a selective agonist of the ghrelin / growth-hormone secretagogue receptor (GHS-R1a). In research models the two are frequently co-formulated to study additive stimulation of somatotroph growth-hormone release.
Documentation
batch-document availability confirmed by product, specification and applicable lot. Distribution scope confirmed before invoicing.
Reverse-phase HPLC with UV detection; purity target reported per lot with related-substance reporting on request.
Mass spectrometry identity confirmation against the CJC-1295 without DAC + Ipamorelin reference profile.
Compound prefix and lot serial printed on the vial label and repeated in the document pack and carton.
FAQ
Each vial contains two lyophilized peptides co-formulated together: CJC-1295 without DAC — also called Modified GRF (1-29), a GHRH analog — and ipamorelin (CAS 170851-70-4), a selective ghrelin-receptor agonist. The per-vial ratio and total peptide content are stated on the batch documentation and confirmed on RFQ.
No — a blend is a physical mixture of two distinct peptides, so it has no single molecular weight. The batch COA reports chromatographic purity and component molecular-weight identity criteria rather than assigning one mass figure to the mixture.
The current lot is supported by a batch COA containing a chromatographic purity result, component molecular-weight identity criteria, water-content and appearance results. Current-batch documentation is available for review before payment on qualifying orders.
The blend is stocked as lyophilized powder in 10 mg vials with a minimum order of 1 kit (10 vials). Fill ratios, alternative vial sizes and private-label / OEM packaging can be quoted on request.
No. It is supplied strictly as a research-use reference material for laboratory and manufacturing customers. We confirm buyer context and destination country before invoicing and do not provide dosing or medical guidance.
Related compounds
Current Batch COA
Batch-linked COA PDF for each CJC-1295 No DAC + Ipamorelin specification below, with the reported chromatographic purity and molecular-weight identity results. Independent local verification is welcome. Confirmed quality issues are eligible for replacement or refund under the quality policy.